Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,
is pleased to announce its interim results for the half year ended 31 August
2005.

Financial Highlights

   * Sales up 35.5% to £7.5m
   * Profit after tax, on an IFRS basis was £385K
   * Gross margin improvement of 53.6%
   * Operating cashflow remains strong at £1.6m
   * Basic earnings per share of 0.26p
   * Financial year changing to December 31st - commencing December 2005

Operational Highlights

   * Phase III clinical trials on Isprelor(TM), (induction of labour)

      - trials expected to complete the middle of 2006

   * Phase III trials on Posidorm(TM), (melatonin for sleeping disorders),

      - on track for introduction in 2007

   * Selective acquisition of reputable prescription brands under discussion

Commenting on the results, Michael Gatenby, Alliance Pharma's Chairman, said:
'Our interim results for the 6 months to August 2005 represent another period of
good, on-target, performance from the current business with solid progress also
being made on the development projects. Significant progress has also been made
in building and strengthening the managerial team...... We look forward to the
next half year with continued optimism.'